Clinical Trial Update: Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LY-2940094 for protection against stress-induced depression and anxiety phenotypes has been withdrawn before completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder

Drugs mentioned

• LY-2940094

Snippet

Sponsor: Mclean Hospital | Conditions: Depression - Major Depressive Disorder, Anxiety | Phase 2 | Status: WITHDRAWN